K-Ras G12C-IN-3 is primarily used in research and development for targeting specific mutations in cancer therapy. It is designed to inhibit the K-Ras G12C mutant protein, which is commonly found in various cancers such as lung, colorectal, and pancreatic cancers. By selectively binding to the mutated protein, it helps to block the signaling pathways that promote tumor growth and survival. This compound is a valuable tool in preclinical studies to evaluate the efficacy of K-Ras inhibitors and to explore potential therapeutic strategies for treating cancers driven by K-Ras mutations. Its application contributes to advancing precision medicine by offering a targeted approach to combat resistant and hard-to-treat cancers.